Therapeutic Asset Ratings

315 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Adrenomedullin Acute Myeloid Leukemia	Gruppo Italiano Malattie EMatologiche dell'Adulto	N/A	D (26)
Alloreactive Nk Cell Infusion Acute Myeloid Leukemia	IRCCS Azienda Ospedaliero-Universitaria di Bologna	N/A	D (26)
DEXKETOPROFEN Acute Myeloid Leukemia	Peking University People's Hospital	N/A	D (26)
INTERFERON ALPHA 1B Acute Myeloid Leukemia	Henan Cancer Hospital	N/A	D (26)
METAMIZOLE Acute Myeloid Leukemia	Peking University People's Hospital	N/A	D (26)
METARAMINOL Acute Myeloid Leukemia	Peking University People's Hospital	N/A	D (26)
Midodrine Acute Myeloid Leukemia	Peking University People's Hospital	N/A	D (26)
NORADRENALINE TARTRATE IMPURITY C Acute Myeloid Leukemia	Peking University People's Hospital	N/A	D (26)
Plavix Acute Myeloid Leukemia	Peking University People's Hospital	N/A	D (26)
Thalidomide Acute Myeloid Leukemia	Henan Cancer Hospital	N/A	D (26)
Autologous Hla-A*02:01-Restricted Cd4+/Cd8+ Anti-Wt1 Tcr/Cd8Ab-Expressing T-Cells Acute Myeloid Leukemia	Fred Hutchinson Cancer Center	P1	NR (0)
Autologous HLA-A*02:01-restricted CD4+ T-cells Acute Myeloid Leukemia	Fred Hutchinson Cancer Center	P1	NR (0)
ncr300 Acute Myeloid Leukemia	Nuwacell Biotechnologies Co., Ltd.	P1	NR (0)
Plm-102 Acute Myeloid Leukemia	M.D. Anderson Cancer Center	P1	NR (0)
il3 car t-cells Acute Myeloid Leukemia	Zhejiang University	Early P1	NR (0)

Showing 301 to 315 of 315 assets

PreviousPage 13 of 13Next